The Superior Court of Justice of the Canadian Province of Ontario approved the sale of Transition Therapeutics Inc. of Toronto to OPKO Health Inc. of Miami on Aug. 29. The deal was for $60 million to be paid in the form of 6.4 million shares of OPKO common stock distributed to Transition shareholders in exchange for their shares of Transition common stock.
Dr. Phillip Frost, chairman and CEO of OPKO, and his counterpart at Transition, Dr. Tony Cruz, reached an agreement in early May. That was when a team of Greenberg Traurig attorneys went to work, led by Robert Grossman and Joshua Samek. Both are based in Miami.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
